Book a free consultation
A no-obligation conversation with our care team, arranged through KPCIRC.
Book a consultationPillar 4 · surveillance after treatment
Clear
Continuous surveillance for people who have finished curative-intent treatment and want the earliest possible warning if cancer returns.
Surveillance after curative-intent treatment
Watching, quietly, after treatment ends
Clear is continuous surveillance for people who have finished curative-intent treatment and want the earliest possible warning if cancer returns.
It watches in the background for the faint molecular signal of disease, long before a scan could see it.
Why it matters
Earlier warning
Trace ctDNA can flag returning disease months ahead of imaging, when more options may still be open.
Peace of mind
Between scans, reassurance grounded in molecular data rather than waiting.
Personalised follow-up
Results can inform how closely you are watched and when to investigate.
Clear or Sentinel?
Clear is for after treatment. Sentinel is for during it.
| Clear | Sentinel | |
|---|---|---|
| When | After curative-intent treatment | During active treatment for advanced disease |
| The question | Is anything left, is it returning? | Is this working, is resistance emerging? |
| Watching for | Molecular residual disease | Response, progression and resistance |
| Your situation | Remission surveillance | On therapy now |
The two Clear tests
Clear Blood
MRD surveillance for blood-based and haematological contexts. See Clear Blood
Clear Solid
Tumour-informed MRD surveillance for solid tumours. See Clear Solid
How monitoring runs
A baseline is established, then Clear monitors at planned intervals on a subscription. Each result is read in context. A rising or newly detected signal triggers a clinician review through KPCIRC, not an automated alarm.
Research and evidence
The science behind this
ctDNA-based MRD detection is among the most actively validated ideas in oncology today.
Study 1
Post-surgery ctDNA predicts recurrence
In stage II colon cancer, detectable ctDNA after surgery identified patients at much higher risk of recurrence, well before imaging changed.
Tie J, et al. Science Translational Medicine, 2016.
Study 2
Confirmed at large scale
Across 2,240 patients, ctDNA positivity in the post-surgery window was strongly associated with worse disease-free and overall survival.
Nakamura Y, et al. (CIRCULATE-Japan GALAXY) Nature Medicine, 2024.
Study 3
It can guide treatment intensity
A randomized trial showed a ctDNA-guided approach let many patients safely avoid adjuvant chemotherapy without a higher recurrence rate.
Tie J, et al. (DYNAMIC) New England Journal of Medicine, 2022.
These independent, peer-reviewed studies describe the class of technology we use. They are shared for education. They are not results for any individual and not a promise of benefit.
Being clear about our limits
What we do and do not do
What we DO
- Watch for returning disease after curative-intent treatment
- Often flag recurrence earlier than routine imaging
- Trigger a KPCIRC clinician review on a changing signal
- Personalise how closely follow-up is done
What we DON’T do
- Diagnose recurrence on its own, findings are confirmed
- Detect every recurrence, since some tumours shed little ctDNA
- Replace your scheduled scans and specialist follow-up
- Guarantee that acting earlier will change the outcome
Plain-language glossary (5 terms)
| Term | What it means |
|---|---|
| MRD | Molecular residual disease, microscopic disease left after treatment. |
| ctDNA | Circulating tumour DNA, tumour fragments a blood test can read. |
| Tumour-informed | An MRD test built from your own tumour’s mutations, for higher sensitivity. |
| Recurrence | The cancer returning after a period of remission. |
| Lead time | How far ahead of a scan a blood test can flag returning disease. |
Important information and regulatory status
Clear is a genomic (DNA-based) test for use by qualified healthcare professionals. It supports clinical judgement, it does not replace it, and it must be read alongside your full clinical history and applicable guidelines.
- A result is not a diagnosis and does not by itself decide treatment.
- A “not detected” result does not rule out cancer or a genetic change.
- Not all cancers release enough DNA into blood to be detected.
- We cannot guarantee that a medicine will be available, approved, covered or effective.
- Collection kits are for qualified phlebotomists. They are not for self-testing.
- Confirmatory testing may be required.
Regulatory status (India). Registration of our genomic tests as in-vitro diagnostic (IVD) medical devices with CDSCO is in progress, with the IVD class pending. Sequencing and variant calling are done by an accredited laboratory partner holding NABL (ISO 15189), CAP and CLIA accreditation, following ACMG/AMP/ASCO/CAP guidelines and a CE-IVD certified variant database. The OnKommon interpretation engine is provided for research and decision-support use. Marketing follows the Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954.
Take the next step
Three ways forward. Pick the one that fits today.
Begin Blueprint Care
Commission your decision report and a dedicated clinical team.
Explore Blueprint CareAsk on WhatsApp, free
Signal replies to your first question within four hours, at no cost.
Start with Signal